Skip to main content
    K

    Kiniksa Pharmaceuticals Ltd (KNSA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $94.23
    -2.10 (-2.18%)

    Market Cap: $7.57B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kiniksa Pharmaceuticals Ltd (KNSA) Government Contracts

    Updated Aug 4, 2026. Contract data from federal award records.

    Federal agencies obligated $328,283 to Kiniksa Pharmaceuticals over the 12 months through Jul 31, 2026. That is less than 1% of its revenue. Department of Veterans Affairs was its only awarding agency.

    Federal Obligations

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated.

    Obligations
    $328,283
    Obligations to revenue
    0.0%
    Prior 12 months$355,009
    Contracts with activity6
    New contracts5
    Top agencyDepartment of Veterans Affairs
    Top agency share100.0%
    Agencies1
    Average remaining term4.3 months

    12 months through Jul 31, 2026

    Largest New Awards

    The 5 largest new awards total $354,484, and the largest makes up 62.1% of that.

    Award IDAgencyAmountStartEndDescription
    36C26026F0076Department of Veterans Affairs$220,229Dec 15, 2025Dec 14, 2026BULK - ARCALYST 220MG VIL
    36C24526N0294Department of Veterans Affairs$34,023Jan 31, 2026Feb 4, 2026ARCALYST 200 MG
    36C24526N0418Department of Veterans Affairs$34,023Mar 18, 2026Mar 24, 2026ARCALYST 200 MG
    36C24526N0595Department of Veterans Affairs$34,023May 21, 2026May 27, 2026ARCALYST 220 MG
    36C24526N0196Department of Veterans Affairs$32,187Dec 22, 2025Dec 30, 2025ARCALYST 200 MG
    New federal contracts awarded in the 12 months through Jul 31, 2026, largest first. All from the Department of Veterans Affairs.

    Monthly Obligations

    The latest complete month, Apr 2026, had no net obligations. The largest month in the table was Oct 2025, at $209,215.

    MonthObligations
    Jul 2026$0
    Jun 2026$0
    May 2026$34,023
    Apr 2026$0
    Mar 2026$34,023
    Feb 2026$11,015
    Jan 2026$34,023
    Dec 2025$32,187
    Nov 2025-$26,201
    Oct 2025$209,215
    Sep 2025$0
    Aug 2025$0
    MonthObligations
    Jul 2025-$48,280
    Jun 2025$0
    May 2025$0
    Apr 2025$191
    Mar 2025$5,533
    Feb 2025$0
    Jan 2025$190,832
    Dec 2024$206,734
    Nov 2024$0
    Oct 2024$0
    Sep 2024$0
    Aug 2024$0

    Net obligations recorded each month, newest first. Agencies report contract actions with a delay (the Defense Department about 90 days), so the latest months, May to Jul 2026, are still incomplete and the 12-month total usually rises as agencies report the rest.

    Frequently Asked Questions About KNSA

    How much does Kiniksa Pharmaceuticals receive in federal contracts?

    Kiniksa Pharmaceuticals had $328,283 in federal contract obligations over the 12 months through Jul 31, 2026, compared with $355,009 in the 12 months before. Obligations are contract bookings by the awarding agency, not recognized revenue.

    What are Kiniksa Pharmaceuticals' largest government contracts?

    The largest new awards over the 12 months through Jul 31, 2026 were 36C26026F0076, Department of Veterans Affairs, $220,229, started Dec 15, 2025; 36C24526N0294, Department of Veterans Affairs, $34,023, started Jan 31, 2026; 36C24526N0418, Department of Veterans Affairs, $34,023, started Mar 18, 2026.

    Which agencies award Kiniksa Pharmaceuticals contracts?

    Department of Veterans Affairs was its only awarding agency over the 12 months through Jul 31, 2026.

    What new federal contracts did Kiniksa Pharmaceuticals win in the 12 months through Jul 31, 2026?

    Kiniksa Pharmaceuticals won 5 new federal contracts in the 12 months through Jul 31, 2026. The largest was 36C26026F0076, Department of Veterans Affairs, $220,229, started Dec 15, 2025.

    How do Kiniksa Pharmaceuticals' federal obligations compare with its revenue?

    Federal contract obligations were $328,283 over the 12 months through Jul 31, 2026, equivalent to less than 1% of Kiniksa Pharmaceuticals' revenue. Obligations are amounts the government committed to contracts in the period, not the share of Kiniksa Pharmaceuticals' revenue that comes from the government.